UNLABELLED: Bone collagen maturation may be important for anti-fracture efficacy as the reduction in risk is only partly explained by a concomitant increase in BMD during anti-resorptive therapy. Different treatments caused diverse profiles in bone collagen degradation products, which may have implications for bone quality. INTRODUCTION: The aim of the present study was to evaluate the effect of different anti-resorptive treatments on bone collagen maturation measured as the ratio between the degradation products of newly synthesized and mature isomerized C-telopeptides of type I collagen. METHODS:Participants were from cohorts of healthy postmenopausal women participating in double blind, placebo-controlled 2-year studies ofalendronate, ibandronate, intranasal hormone replacement therapy (HRT), oral HRT, transdermal HRT, or raloxifene (n = 427). The non-isomerized alphaalphaCTX and isomerized betabetaCTX were measured in urine samples obtained at baseline, and after 6, 12, and 24 months of therapy. RESULTS:Bone collagen maturation measured as the ratio between alphaalphaCTX and betabetaCTX showed that bisphosphonate treatment induced a collagen profile consistent with an older matrix with a 52% (alendronate) and 38% (ibandronate) reduction in the ratio between the two CTX isoforms vs. 3% and 15% with HRT or raloxifene, respectively. CONCLUSIONS:Anti-resorptive treatments had different effects on the endogenous profile of bone collagen maturation. Whether that effect on bone collagen has an impact on bone strength independent on the treatment-dependent effect on BMD should be investigated.
RCT Entities:
UNLABELLED: Bone collagen maturation may be important for anti-fracture efficacy as the reduction in risk is only partly explained by a concomitant increase in BMD during anti-resorptive therapy. Different treatments caused diverse profiles in bone collagen degradation products, which may have implications for bone quality. INTRODUCTION: The aim of the present study was to evaluate the effect of different anti-resorptive treatments on bone collagen maturation measured as the ratio between the degradation products of newly synthesized and mature isomerized C-telopeptides of type I collagen. METHODS:Participants were from cohorts of healthy postmenopausal women participating in double blind, placebo-controlled 2-year studies of alendronate, ibandronate, intranasal hormone replacement therapy (HRT), oral HRT, transdermal HRT, or raloxifene (n = 427). The non-isomerized alphaalphaCTX and isomerized betabetaCTX were measured in urine samples obtained at baseline, and after 6, 12, and 24 months of therapy. RESULTS: Bone collagen maturation measured as the ratio between alphaalphaCTX and betabetaCTX showed that bisphosphonate treatment induced a collagen profile consistent with an older matrix with a 52% (alendronate) and 38% (ibandronate) reduction in the ratio between the two CTX isoforms vs. 3% and 15% with HRT or raloxifene, respectively. CONCLUSIONS: Anti-resorptive treatments had different effects on the endogenous profile of bone collagen maturation. Whether that effect on bone collagen has an impact on bone strength independent on the treatment-dependent effect on BMD should be investigated.
Authors: Paul D Miller; Ethel S Siris; Elizabeth Barrett-Connor; Kenneth G Faulkner; Lois E Wehren; Thomas A Abbott; Ya-Ting Chen; Marc L Berger; Arthur C Santora; Louis M Sherwood Journal: J Bone Miner Res Date: 2002-12 Impact factor: 6.741
Authors: Somnath Sarkar; Bruce H Mitlak; Mayme Wong; John L Stock; Dennis M Black; Kristine D Harper Journal: J Bone Miner Res Date: 2002-01 Impact factor: 6.741
Authors: Nelson B Watts; Cyrus Cooper; Robert Lindsay; Richard Eastell; Michael D Manhart; Ian P Barton; Tjeerd-Pieter van Staa; Jonathan D Adachi Journal: J Clin Densitom Date: 2004 Impact factor: 2.963
Authors: D J Leeming; K Henriksen; I Byrjalsen; P Qvist; S H Madsen; P Garnero; M A Karsdal Journal: Osteoporos Int Date: 2009-03-28 Impact factor: 4.507
Authors: Janet L Huebner; Anne C Bay-Jensen; Kim M Huffman; Yi He; Diana J Leeming; Gary E McDaniel; Morten A Karsdal; Virginia B Kraus Journal: Arthritis Rheumatol Date: 2014-09 Impact factor: 10.995
Authors: Samuel Gourion-Arsiquaud; Matthew R Allen; David B Burr; Deepak Vashishth; Simon Y Tang; Adele L Boskey Journal: Bone Date: 2009-11-17 Impact factor: 4.398
Authors: Patrick Garnero; Doug C Bauer; Emmanuel Mareau; John P Bilezikian; Susan L Greenspan; Clifford Rosen; Dennis Black Journal: J Bone Miner Res Date: 2008-09 Impact factor: 6.741